Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

From ₹5,000 salary to ₹48 crore turnover: Meet Nayana Vaidya, a pharma saleswoman, who built a healthcare distribution company from scratch

Nayana Vaidya built Om Sai Surgicals from a modest beginning. Her company achieved a turnover of nearly ₹48 crore. Vaidya finds satisfaction in the work itself, not just the financial success. Her journey highlights patience and steady growth in the healthcare distribution sector. She earned her first crore around 2010.

The Economic Times

Stereotaxis Q1 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system. Chairman and CEO David Fischel told investors that t

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company beg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Dividend Aristocrats With Soaring Profits That Wall Street Says to Buy Now

3 Dividend Aristocrats with strong profit growth, safe payout ratios, decades of raises, and Buy-rated Wall Street support.

Foreign aid’s hidden benefit: Recipients are more likely to pay the generosity forward

Foreign aid may not improve how recipients view donor countries – but it can set off a chain of goodwill that spreads far beyond the original act of giving.

The Conversation

Johnson & Johnson Plans to Sell Prescription Drugs to TrumpRx in Cost-Reduction Push

Johnson & Johnson will sell diabetes and blood thinner drugs on TrumpRx as part of a U.S. push to reduce prescription medication costs.

International Business Times

3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

inkl

Read news from The Economist, FT, and more,
with one subscription

5 Stocks to Buy With Your 2026 Tax Refund

5 Stocks to Buy With Your 2026 Tax Refund

Wondering what to do with your tax refund? Investing in high-quality stocks is one option and these five picks are a good place to start.

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

JNJ stock is on track to rally higher after better-than-expected results. Cash flow and growth say this dividend story is reliable.

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

This Dividend King offers a rare mix of safety and upside heading into earnings.

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

A Q2 2026 Playbook for Navigating Market Uncertainty

A Q2 2026 Playbook for Navigating Market Uncertainty

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

2 Safe Dividend Stocks to Buy and Hold Forever

2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

From pilot mania to portfolio discipline: how the best companies are escaping AI purgatory

From pilot mania to portfolio discipline: how the best companies are escaping AI purgatory

Most companies have dozens of AI pilots and almost nothing to show for it. The ones breaking through have stopped experimenting and started betting.

Get all your
news in one place.

100's of premium titles.
One news app.

When Fear Hits the Stock Market, Where Can Investors Find Safety?

Our senior market strategist takes a look at traditionally defensive sectors to find opportunities in the current market uncertainty.

Is There Such a Thing As a Safe Stock? 17 Safe-Enough Ideas

No stock is completely safe, but we can make educated guesses about which ones are likely to provide smooth sailing.

The Conversation

What’s the link between talcum powder and cancer?

More than 1,300 Victorians have joined a class action against Johnson & Johnson alleging its talcum powder products left them with ovarian cancer, mesothelioma (cancer affecting the lungs) and other cancers affecting the reproductive organs.

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

Get all your
news in one place.

100's of premium titles.
One news app.

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

5 Dividend Stocks Retirees Are Favoring for Steady Income in 2026

Retirees in 2026 are looking for something simple: predictable income without unnecessary risk. With inflation still pressuring household budgets and bond yields bouncing around, many...

Anger, distress but $405m mesh implant payouts coming

Exasperation over lengthy wait for women to be compensated for pelvic mesh implant injuries has led to promises that money will start flowing soon.

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

1 2 3 4 5

People

189,192 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Medical Technology

Places

373,403 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play